EUFLEXXA
Device
Ferring Pharmaceuticals Inc.
Total Payments
$2.0M
Transactions
47,614
Doctors
11,388
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $96,126 | 5,050 | 2,509 |
| 2023 | $112,524 | 5,286 | 2,604 |
| 2022 | $139,194 | 5,468 | 2,867 |
| 2021 | $78,534 | 4,376 | 2,297 |
| 2020 | $61,595 | 2,490 | 1,413 |
| 2019 | $329,347 | 5,704 | 2,524 |
| 2018 | $664,857 | 9,386 | 3,782 |
| 2017 | $557,714 | 9,854 | 3,512 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $808,761 | 46,153 | 39.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $582,306 | 230 | 28.5% |
| Unspecified | $324,287 | 10 | 15.9% |
| Consulting Fee | $198,594 | 47 | 9.7% |
| Travel and Lodging | $117,870 | 516 | 5.8% |
| Education | $8,074 | 658 | 0.4% |
Payments by Type
General
$1.7M
47,604 transactions
Research
$324,287
10 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Pilot Study to Evaluate Efficacy and Safety of Euflexxa for the Treatment of Osteoarthritis | Ferring Pharmaceuticals Inc. | $235,856 | 0 |
| Retrospective Study to Evaluate PatientsClinical Factors related to Positive Response from HA Injections | Ferring Pharmaceuticals Inc. | $78,030 | 0 |
| A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome | Ferring Pharmaceuticals Inc. | $9,382 | 0 |
Top Doctors Receiving Payments for EUFLEXXA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Scott Bruder | — | Franklin Lakes, NJ | $325,556 | 12 |
| , MD | Sports Medicine | Dallas, TX | $97,214 | 154 |
| Stanley Dysart | — | Marietta, GA | $82,082 | 101 |
| , MD | Orthopaedic Surgery | Lexington, KY | $79,011 | 70 |
| , MD | Orthopaedic Surgery | Van Nuys, CA | $76,787 | 130 |
| , M.D | Adult Reconstructive Orthopaedic Surgery | Cleveland, OH | $48,150 | 3 |
| , M.D | Family Medicine | Apex, NC | $37,069 | 92 |
| , MD | Physical Medicine & Rehabilitation | Overland Park, KS | $35,663 | 70 |
| , M.D | Orthopaedic Surgery | Denver, CO | $28,904 | 43 |
| , M.D | Sports Medicine | Flushing, NY | $28,687 | 39 |
| , MD | Orthopaedic Surgery | Allentown, PA | $27,221 | 29 |
| , D.O | Internal Medicine | Lexington, KY | $21,483 | 43 |
| , MD | Orthopaedic Surgery | Stockbridge, GA | $21,103 | 24 |
| , MD | Sports Medicine | Provo, UT | $20,093 | 50 |
| , M.D | Family Medicine | Colleyville, TX | $19,311 | 48 |
| , D.O | Student in an Organized Health Care Education/Training Program | Lorain, OH | $18,508 | 34 |
| , MD | Family Medicine | San Diego, CA | $17,796 | 31 |
| , MD | Orthopaedic Surgery | Nanuet, NY | $17,674 | 27 |
| , M.D | Orthopaedic Surgery | Richfield, UT | $16,110 | 25 |
| , M.D | Sports Medicine | Toledo, OH | $15,929 | 39 |
| , MD | Rheumatology | Minneapolis, MN | $15,857 | 42 |
| , M.D | Family Medicine | Los Angeles, CA | $15,737 | 35 |
| , MD | Family Medicine | Rochester, NY | $14,817 | 48 |
| , DO | Family Medicine | Virginia Beach, VA | $13,490 | 56 |
| , M.D | Sports Medicine | Egg Harbor Township, NJ | $13,017 | 57 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $2.0M
- Total Doctors 11,388
- Transactions 47,614
About EUFLEXXA
EUFLEXXA is a device associated with $2.0M in payments to 11,388 healthcare providers, recorded across 47,614 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $96,126 was paid across 5,050 transactions to 2,509 doctors.
The most common payment nature for EUFLEXXA is "Food and Beverage" ($808,761, 39.6% of total).
EUFLEXXA is associated with 3 research studies, including "A Prospective Pilot Study to Evaluate Efficacy and Safety of Euflexxa for the Treatment of Osteoarthritis" ($235,856).